Compare Merck & Co., Inc. (MRK) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs State Street Technology Select Sector SPDR ETF — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while State Street Technology Select Sector SPDR ETF trades at $180.5. The key difference: Merck & Co., Inc. pays a 2.73% dividend while State Street Technology Select Sector SPDR ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, State Street Technology Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals.
| MRK | XLK | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Sector/Thematic |
52-Week High | $129.52 | $198.21 |
52-Week Low | $77.60 | $127.49 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
XLK, the Technology Select Sector SPDR Fund, trades at $175.71 with a slight 0.07% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators are neutral. The fund has delivered strong year-to-date performance, up 33% as of July 2, 2026 (ETF Trends), but faces concentration risks in mega-cap tech holdings. Recent news highlights ongoing institutional interest in tech ETFs amid robust earnings expectations for the sector.
The outlook for XLK remains tied to technology sector strength, with Q2 earnings expected to show 23.3% growth for the S&P 500 (ETF Trends, July 13, 2026). Key risks include sector concentration and market volatility. Wall Street sentiment is positive due to strong fundamentals, but investors should monitor earnings results and Fed policy impacts on growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
